Cell & gene therapy manufacturing · Riyadh
Hayyan Cellworks is an academic-hybrid contract development and manufacturing organisation for advanced therapy medicinal products, founded in collaboration with King Faisal Specialist Hospital & Research Centre under the National Biotechnology Strategy.
The heritage anchor
Twelve hundred years ago, in workshops across Kufa and Baghdad, the Arab polymath Jabir ibn Hayyan — known to medieval European universities as Geber — introduced experimental method to chemistry. He isolated mineral acids, codified distillation, and named the apparatus he invented: the al-anbīq — the alembic.
The alembic is not a metaphor. It is the founding instrument of bioprocess. Distillation became extraction, became fermentation, became the unit operations of every modern biomanufacturing facility. The continuity is unbroken — only the molecule changed.
Hayyan Cellworks takes that name and that lineage as its operating reference. Evidence-led. Method-disciplined. Built to be inspected, audited, and reproduced — the discipline that makes a process pharmaceutical-grade.
Capabilities
The facility activates in clusters, gated by capability and demand. Each cluster operates under a single quality system, a single tech-transfer methodology, and an independent quality reporting line — the structural separation that makes the facility SFDA-credible from day one.
Autologous and allogeneic CAR-T manufacturing, with closed-system processes scoped for regional patient demand and academic in-licensing.
Lentiviral vector production for in-house cell-therapy use, with extension to MENA-region academic and biotech partners.
Activated under documented capability, demand, and financial-sustainability gates. Scoped for Saudi-genome haplobank potential and selective in-licensing.
The Academic-Hybrid model
Discovery and manufacturing require fundamentally different mindsets. The Wall is the structural separation that preserves discovery velocity on one side and manufacturing discipline on the other — connected by governed handoffs and independent quality reporting.
Discovery-driven sandbox. Hospital and academic collaborators on TRL 1–5 work, with industry partner co-development.
Process development at lab scale. Scale-up engineering trials, analytical method development, tech-transfer documentation.
Validated manufacturing only. Batch release, quality systems, SFDA cadence, independent QA reporting line outside operations.
How we are governed
Three anchors decide every modality, every contract, every capacity request. A neither-hospital-nor-pure-CDMO operating model — the only structure that protects all three simultaneously.
Hospital pharmacy lacks scale and cadence. Tech transfer becomes improvised; partnership credibility never accrues; patient mission becomes capacity-bound.
Pure CDMO disconnects from mission. The clinical-research loop severs; patient priority becomes secondary to margin; the Vision 2030 anchor role is forfeited.
Hybrid Academic-CDMO is a new species for cell therapy: research-anchored, GMP-disciplined, patient-led, partner-orchestrating. The competitive moat capacity cannot match.
Every modality, partnership, and capacity request passes three filters in order:
Filter 01 · Clinical fit. Real patient need at KFSHRC plus credible capability today, or an obvious extension of it.
Filter 02 · Demand and sustainability. Credible volume path that pays its own way within the activation horizon.
Filter 03 · Strategic anchor. Strengthens the regional ATMP hub identity and serves the National Biotechnology Strategy.
Three passes → yes. Two → not yet, with conditions. One or zero → not now. The framework decides; the framework is the answer.
Leadership
Site Head and Quality Site Head report independently to the standalone-entity board through 2030, after which the facility re-integrates into KFSHRC governance under the ATMP Programme Committee. Leadership announcements timed to facility commissioning gates.
Operator-provided through Years 1–3 under the Build-Operate-Transfer mandate. Saudi successor in 1:1 pairing from Year 3 onward.
Announcement Q3 2026
Reports outside operations, separate line to the standalone-entity board. Saudi successor pairing matches site-leadership cadence.
Announcement Q4 2026
Saudi-track from day one. Owns BD pipeline, in-licensing negotiations, CDMO contract evaluation, and out-licensing of KFSH-developed IP.
Announcement H1 2027Portraits shown are illustrative imagery for the working brand preview. Final leadership photography will replace these placeholders following the announcements scheduled above.
Insights
Patient mission, financial sustainability, and regional prominence cannot all be served by a hospital pharmacy or a pure CDMO. The hybrid is the structural answer — not a compromise.
Read the framing →Allogeneic platforms, gene editing beyond Casgevy, and Saudi haplobank programmes all converge on a single capability: regional LV vector supply. The case for activating Cluster 02 alongside Cluster 01.
Read the brief →Distillation became extraction, became unit operation. The heritage anchor of the Hayyan name is not decorative — it is the founding methodology of every modern bioprocess.
Read the essay →For in-licensing enquiries, CDMO contract discussion, or academic collaboration on advanced therapies in the MENA region.
partner@hayyancellworks.com